GOVX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	141 330
Gjennomsnittsvolum	39 047.00
Markedsverdi	3.72M
EPS	$0 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.110
ATR14	$0.0270 (1.68%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Dodd David A	Buy	8 209	Common Stock
2024-02-21	Dodd David A	Buy	520	Common Stock
2024-02-07	Reynolds Mark	Buy	2 000	Common Stock
2023-12-22	Mckee Kelly T. Jr.	Buy	6 944	Common Stock
2023-09-25	Mckee Kelly T. Jr.	Buy	9 653	Common Stock

INSIDER POWER
99.75
Last 95 transactions
Buy: 15 241 679 \| Sell: 50 000

Volum Korrelasjon

Lang: 0.19 (neutral)

Kort: 0.79 (moderate)

Signal:(57.751) Neutral

GeoVax Labs, Inc. Korrelasjon

10 Mest positive korrelasjoner
IRBT	0.975
ENNV	0.971
FWRD	0.968
MNSB	0.967
KRNY	0.967
PLL	0.967
WALD	0.962
SINT	0.962
TSLA	0.959
PRSO	0.959

10 Mest negative korrelasjoner
NVCN	-0.97
FTIV	-0.97
FLXS	-0.965
ITMR	-0.965
ROVR	-0.963
AVEO	-0.961
ADTH	-0.956
TIOAU	-0.953
MSVB	-0.952
KVSC	-0.952

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

GeoVax Labs, Inc. Korrelasjon - Valuta/Råvare

-0.04
( neutral )

0.16
( neutral )

0.00
( neutral )

-0.44
( neutral )

-0.29
( neutral )

GeoVax Labs, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-74 169.00 (0.00 %)
EPS:	$-14.29

FY	2023
Omsetning:	$0
Bruttogevinst:	$-74 169.00 (0.00 %)
EPS:	$-14.29

FY	2022
Omsetning:	$81 000.00
Bruttogevinst:	$24 716.00 (30.51 %)
EPS:	$-12.39

FY	2021
Omsetning:	$385 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.04

Financial Reports:

No articles found.

GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.